Targeted Covalent Inhibitors for Drug Design
The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Abstract
In contrast to the traditional mechanism of drug action that relies on the reversible, noncovalent interaction of a ligand with its biological target, a targeted covalent inhibitor (TCI) is designed such that the initial, reversible association is followed by the formation of a covalent bond between an electrophile on the ligand and a nucleophilic center in the protein. Although this approach offers a variety of potential benefits (high potency and extended duration of action), concerns over the possible toxicological consequences of protein haptenization have hindered the development of the TCI concept. Recently, approaches to mitigate the risk of serious adverse reactions to this new class of agent have emerged, thus stimulating interest in the field and leading to authorization of the first cadre of TCIs to be marketed. The covalent inhibitor approach is rapidly gaining acceptance as a valuable tool in drug discovery, and is poised to make a major impact on the design of enzyme inhibitors and receptor modulators.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, the oxidation of drugs such as furosemide, isoniazid, acetaminophen, halothane, and model hepatotoxins via cytochrome P-450 can lead to hepatotoxic effects in animals and humans [131, 132].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [132]
Citations
Cites
The growing applications of click chemistry
Moses, J. E., & Moorhouse, A. D. (2007) · Chem. Soc. Rev. · doi:10.1039/b613014n · Cited by 2,367
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Self-citationCommon and Uncommon Cytochrome P450 Reactions Related to Metabolism and Chemical Toxicity
Guengerich, F. P. (2001) · Chemical Research in Toxicology · doi:10.1021/tx0002583 · Cited by 1,655
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
Powers, J. C., Asgian, J. L., Ekici, Ö. D., & James, K. E. (2002) · Chemical Reviews · doi:10.1021/cr010182v · Cited by 1,090
Physiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Kuhn, D. J., Chen, Q., Voorhees, P. M., Strader, J. S., Shenk, K. D., Sun, C. M., Demo, S. D., Bennett, M. K., van Leeuwen, F. W. B., Chanan-Khan, A. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065888 · Cited by 768
Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., & Baillie, T. A. (2004) · Chemical Research in Toxicology · doi:10.1021/tx034170b · Cited by 706
Self-citationStepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 698
Self-citation
Research works printed but not linked: 7
- Parmar S., 2014, Pharm. Ther., 39, 483
- Johansson M. H., 2012, Mini-Rev. Med. Chem., 12, 1330
- Campuzano I. D. G., 2015, J. Biomol. Screening, 1
- Guerciolini R., 1997, Int. J. Obes., 21, 12
- Kumar S., 2008, Curr. Opin. Drug Discovery Dev., 11, 43
- Strelevitz T. J., 2015, Drug Metab. Rev., 47, 59
- The Wall Street Journal December 2 2015.
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“565,567,573”
Gehringer, M., & Laufer, S. A. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01153 · Cited by 714
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
Douangamath, A., Fearon, D., Gehrtz, P., Krojer, T., Lukacik, P., Owen, C. D., Resnick, E., Strain-Damerell, C., Aimon, A., Ábrányi-Balogh, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18709-w · Cited by 526
Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles
Eaton, J. K., Furst, L., Ruberto, R. A., Moosmayer, D., Hilpmann, A., Ryan, M. J., Zimmermann, K., Cai, L. L., Niehues, M., Badock, V., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0501-5 · Cited by 489
An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells
Vinogradova, E. V., Zhang, X., Remillard, D., Lazar, D. C., Suciu, R. M., Wang, Y., Bianco, G., Yamashita, Y., Crowley, V. M., Schafroth, M. A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.001 · Cited by 351
Advances in covalent kinase inhibitors
Abdeldayem, A., Raouf, Y. S., Constantinescu, S. N., Moriggl, R., & Gunning, P. T. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00720b · Cited by 317
Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening
Resnick, E., Bradley, A., Gan, J., Douangamath, A., Krojer, T., Sethi, R., Geurink, P. P., Aimon, A., Amitai, G., Bellini, D., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b02822 · Cited by 335
Covalent inhibitors design and discovery.
De Cesco, S., Kurian, J., Dufresne, C., Mittermaier, A. K., & Moitessier, N. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.019 · Cited by 315
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
Dai, S., Zhou, Z., Chen, Z., Xu, G., & Chen, Y. (2019) · Cells · doi:10.3390/cells8060614 · Cited by 288
Covalent Inhibition in Drug Discovery
Ghosh, A. K., Samanta, I., Mondal, A., & Liu, W. R. (2019) · ChemMedChem · doi:10.1002/cmdc.201900107 · Cited by 265
A Perspective on Multi-target Drugs for Alzheimer’s Disease
Benek, O., Korabecny, J., & Soukup, O. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.04.008 · Cited by 260
Lysine‐Targeting Covalent Inhibitors
Pettinger, J., Jones, K., & Cheeseman, M. D. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707630 · Cited by 236
The Cysteinome of Protein Kinases as a Target in Drug Development
Chaikuad, A., Koch, P., Laufer, S. A., & Knapp, S. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201707875 · Cited by 225
Tamura, T., Ueda, T., Goto, T., Tsukidate, T., Shapira, Y., Nishikawa, Y., Fujisawa, A., & Hamachi, I. (2018) · Nature Communications · doi:10.1038/s41467-018-04343-0 · Cited by 242
The Ascension of Targeted Covalent Inhibitors
Singh, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02134 · Cited by 193
Bruton tyrosine kinase inhibitors for multiple sclerosis
Krämer, J., Bar-Or, A., Turner, T. J., & Wiendl, H. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00800-7 · Cited by 206
Progress with covalent small-molecule kinase inhibitors
Zhao, Z., & Bourne, P. E. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.035 · Cited by 194
Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity
Lonsdale, R., Burgess, J., Colclough, N., Davies, N. L., Lenz, E. M., Orton, A. L., & Ward, R. A. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00553 · Cited by 190
Qin, H., Zheng, Q., Bare, G. A. L., Wu, P., & Sharpless, K. B. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201608807 · Cited by 185
Cocco, M., Pellegrini, C., Martínez-Banaclocha, H., Giorgis, M., Marini, E., Costale, A., Miglio, G., Fornai, M., Antonioli, L., López-Castejón, G., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01624 · Cited by 165
The Symbiotic Relationship Between Drug Discovery and Organic Chemistry
Grygorenko, O. O., Volochnyuk, D. M., Ryabukhin, S. V., & Judd, D. B. (2020) · Chemistry – A European Journal · doi:10.1002/chem.201903232 · Cited by 174
Biosynthesis and chemical diversity of β-lactone natural products
Robinson, S. L., Christenson, J. K., & Wackett, L. P. (2019) · Natural Product Reports · doi:10.1039/c8np00052b · Cited by 166
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
Kidger, A. M., Sipthorp, J., & Cook, S. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.007 · Cited by 160
Arylfluorosulfate‐Based Electrophiles for Covalent Protein Labeling: A New Addition to the Arsenal
Martín‐Gago, P., & Olsen, C. A. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201806037 · Cited by 164
Cee, V. J., Volak, L. P., Chen, Y., Bartberger, M. D., Tegley, C. M., Arvedson, T., McCarter, J. D., Tasker, A. S., & Fotsch, C. H. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01018 · Cited by 172
The Taxonomy of Covalent Inhibitors
Tuley, A., & Fast, W. L. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00315 · Cited by 167
Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo
Dubiella, C., Pinch, B. J., Koikawa, K., Zaidman, D., Poon, E., Manz, T. D., Nabet, B., He, S., Resnick, E., Rogel, A., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00786-7 · Cited by 173
The role of reversible and irreversible covalent chemistry in targeted protein degradation
Kiely‐Collins, H., Winter, G. E., & Bernardes, G. J. L. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.03.005 · Cited by 163
Comparative Evaluation of Covalent Docking Tools
Scarpino, A., Ferenczy, G. G., & Keserű, G. M. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00228 · Cited by 159
Olea‐Flores, M., Zuñiga‐Eulogio, M. D., Catalán, M. A. M., Rodríguez-Ruiz, H. A., Castañeda-Saucedo, E., Ortuño‐Pineda, C., Padilla‐Benavides, T., & Navarro‐Tito, N. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122885 · Cited by 160
A Survey of the Role of Nitrile Groups in Protein–Ligand Interactions
Wang, Y. E., Du, Y., & Huang, N. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0252 · Cited by 150
Tokunaga, K., Sato, M., Kuwata, K., Miura, C., Fuchida, H., Matsunaga, N., Koyanagi, S., Ohdo, S., Shindo, N., & Ojida, A. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c07490 · Cited by 150
Lysine-Targeted Inhibitors and Chemoproteomic Probes
Cuesta, A., & Taunton, J. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-044805 · Cited by 149
A road map for prioritizing warheads for cysteine targeting covalent inhibitors
Ábrányi‐Balogh, P., Petri, L., Imre, T., Szijj, P. A., Scarpino, A., Hrast, M., Mitrović, A., Fonović, U. P., Németh, K., Barreteau, H., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.010 · Cited by 140
Selective and reversible modification of kinase cysteines with chlorofluoroacetamides
Shindo, N., Fuchida, H., Sato, M., Watari, K., Shibata, T., Kuwata, K., Miura, C., Okamoto, K., Hatsuyama, Y., Tokunaga, K., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-018-0204-3 · Cited by 146
Covalent inhibitors: an opportunity for rational target selectivity
Lagoutte, R., Patouret, R., & Winssinger, N. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.05.008 · Cited by 138
Diacylfuroxans Are Masked Nitrile Oxides That Inhibit GPX4 Covalently
Eaton, J. K., Ruberto, R. A., Kramm, A., Viswanathan, V. S., & Schreiber, S. L. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b10769 · Cited by 134
Moosmayer, D., Hilpmann, A., Hoffmann, J., Schnirch, L., Zimmermann, K. C., Badock, V., Furst, L., Eaton, J. K., Viswanathan, V. S., Schreiber, S. L., et al. (2021) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798320016125 · Cited by 136
Guanidinium-based “molecular glues” for modulation of biomolecular functions
Mogaki, R., Hashim, P. K., Okuro, K., & Aida, T. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00647k · Cited by 131
Dalton, S. E., Dittus, L., Thomas, D. A., Convery, M. A., Nunes, J., Bush, J. T., Evans, J. P., Werner, T., Bantscheff, M., Murphy, J. A., et al. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08979 · Cited by 141
Kalyukina, M., Yosaatmadja, Y., Middleditch, M., Patterson, A. V., Smaill, J. B., & Squire, C. J. (2019) · ChemMedChem · doi:10.1002/cmdc.201800719 · Cited by 130
Zhang, D., Hop, C. E. C. A., Patilea-Vrana, G., Gampa, G., Seneviratne, H. K., Unadkat, J. D., Kenny, J. R., Nagapudi, K., Di, L., Zhou, L., et al. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.086744 · Cited by 130
10 Years Into the Resurgence of Covalent Drugs
Vita, E. D. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0236 · Cited by 139
Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2
Sanders, B., Pokhrel, S., Labbe, A. D., Mathews, I. I., Cooper, C. J., Davidson, R. B., Phillips, G., Weiss, K. L., Zhang, Q., O’Neill, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37254-w · Cited by 129
Diverse Redoxome Reactivity Profiles of Carbon Nucleophiles
Gupta, V., Yang, J. H., Liebler, D. C., & Carroll, K. S. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b01791 · Cited by 126
Mons, E., Jansen, I. D. C., Loboda, J., van Doodewaerd, B. R., Hermans, J., Verdoes, M., van Boeckel, C. A. A., van Veelen, P. A., Turk, B., Türk, V., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b11027 · Cited by 128
Recent Advances in Covalent Drug Discovery
Schaefer, D., & Cheng, X. (2023) · Pharmaceuticals · doi:10.3390/ph16050663 · Cited by 122
Recent advances in the development of covalent inhibitors
Kim, H., Hwang, Y. S., Kim, M., & Park, S. B. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00068c · Cited by 116
Modern Alchemical Free Energy Methods for Drug Discovery Explained
York, D. M. (2023) · ACS Physical Chemistry Au · doi:10.1021/acsphyschemau.3c00033 · Cited by 129
Discovery of Lysine-Targeted eIF4E Inhibitors through Covalent Docking
Wan, X., Yang, T., Cuesta, A., Pang, X., Balius, T. E., Irwin, J. J., Shoichet, B. K., & Taunton, J. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b10377 · Cited by 113
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures
Cheng, W., Yang, Z., Wang, S., Li, Y., Han, W., Tian, X., & Kan, Q. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.003 · Cited by 112
Covalent fragment libraries in drug discovery
Keeley, A. B., Petri, L., Ábrányi‐Balogh, P., & Keserű, G. M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.03.016 · Cited by 117
Wang, L., Ding, J., Pan, L., Cao, D., Jiang, H., & Ding, X. (2021) · Chemometrics and Intelligent Laboratory Systems · doi:10.1016/j.chemolab.2021.104384 · Cited by 111
New Electrophiles and Strategies for Mechanism-Based and Targeted Covalent Inhibitor Design
Ray, S., & Murkin, A. S. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00293 · Cited by 108
Wang, L., Battini, N., Bheemanaboina, R. R. Y., Zhang, S., & Zhou, C. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.072 · Cited by 107
Avoiding drug resistance in HIV reverse transcriptase
Cilento, M. E., Kirby, K. A., & Sarafianos, S. G. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00967 · Cited by 106
Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality
Kostić, M., & Jones, L. H. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.02.006 · Cited by 107
Tunable Methacrylamides for Covalent Ligand Directed Release Chemistry
Reddi, R. N., Resnick, E., Rogel, A., Rao, B. V., Gabizon, R., Goldenberg, K., Gurwicz, N., Zaidman, D., Plotnikov, A. N., Barr, H. M., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c10644 · Cited by 105
Covalent Small Molecules as Enabling Platforms for Drug Discovery
Dalton, S. E., & Campos, S. (2019) · ChemBioChem · doi:10.1002/cbic.201900674 · Cited by 104
Covalent Protein Labeling at Glutamic Acids
Martín‐Gago, P., Fansa, E. K., Winzker, M., Murarka, S., Janning, P., Schultz‐Fademrecht, C., Baumann, M., Wittinghofer, A., & Waldmann, H. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.03.015 · Cited by 103
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98
Expanding the scope of electrophiles capable of targeting K-Ras oncogenes
McGregor, L. M., Jenkins, M. L., Kerwin, C., Burke, J. E., & Shokat, K. M. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00271 · Cited by 97
Keeley, A. B., Ábrányi-Balogh, P., & Keserű, G. M. (2018) · MedChemComm · doi:10.1039/c8md00327k · Cited by 97
Sarkar, A., Concilio, S., Sessa, L., Marrafino, F., & Piotto, S. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101319 · Cited by 95
Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)
Roskoski, R. J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105422 · Cited by 93
Modeling covalent-modifier drugs.
Awoonor-Williams, E., Walsh, A. G., & Rowley, C. N. (2017) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2017.05.009 · Cited by 90
McAulay, K., Hoyt, E. A., Thomas, M. C., Schimpl, M., Bodnarchuk, M. S., Lewis, H. J., Barratt, D. G., Bhavsar, D., Robinson, D. M., Deery, M. J., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b13391 · Cited by 91
Ueda, T., Tamura, T., Kawano, M., Shiono, K., Hóbor, F., Wilson, A. J., & Hamachi, I. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c00703 · Cited by 86
Șandor, A., Ionuţ, I. A., Marc, G., Oniga, I., Eniu, D. T., & Oniga, O. (2023) · Pharmaceuticals · doi:10.3390/ph16040534 · Cited by 90
Aljoundi, A., Bjij, I., El-Rashedy, A. A. E., & Soliman, M. E. S. (2020) · The Protein Journal · doi:10.1007/s10930-020-09884-2 · Cited by 84
The expanding repertoire of covalent warheads for drug discovery
Mehta, N. V., & Degani, M. S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103799 · Cited by 86
Zhu, Q., Saeed, M., Song, R., Sun, T., Jiang, C., & Yu, H. (2019) · Chinese Chemical Letters · doi:10.1016/j.cclet.2019.12.002 · Cited by 79
Natural Molecules Targeting Thioredoxin System and Their Therapeutic Potential
Zhang, J., Duan, D., Osama, A., & Fang, J. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8213 · Cited by 80
Chen, P., Sun, J., Zhu, C., Tang, G., Wang, W., Xu, M., Xiang, M., Zhang, C., Zhang, Z., Gao, L., et al. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202203878 · Cited by 79
Targeted Covalent Modification Strategies for Drugging the Undruggable Targets
Tamura, T., Kawano, M., & Hamachi, I. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00745 · Cited by 79
Birkholz, A. B., Kopecky, D. J., Volak, L. P., Bartberger, M. D., Chen, Y., Tegley, C. M., Arvedson, T., McCarter, J. D., Fotsch, C. H., & Cee, V. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00749 · Cited by 78
Principles and current strategies targeting metallo‐β‐lactamase mediated antibacterial resistance
Yan, Y., Li, G., & Li, G. (2020) · Medicinal Research Reviews · doi:10.1002/med.21665 · Cited by 74
SARS‐CoV‐2 Papain‐Like Protease: Structure, Function and Inhibition
Ullrich, S., & Nitsche, C. (2022) · ChemBioChem · doi:10.1002/cbic.202200327 · Cited by 79
Podoll, T., Pearson, P. G., Evarts, J., Ingallinera, T., Бибикова, Е., Sun, H., Gohdes, M. A., Cardinal, K. A., Sanghvi, M., & Slatter, J. G. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.084459 · Cited by 74
Drugging K-RasG12C through covalent inhibitors: Mission possible?
Ni, D., Li, X., He, X., Zhang, H., Zhang, J., & Lu, S. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.007 · Cited by 73
Development of covalent inhibitors: Principle, design, and application in cancer
Zheng, L., Li, Y., Wu, D., Xiao, H., Zheng, S., Wang, G., & Sun, Q. (2023) · MedComm – Oncology · doi:10.1002/mog2.56 · Cited by 71
Itaconate is a covalent inhibitor of the Mycobacterium tuberculosis isocitrate lyase
Kwai, B. X. C., Collins, A. J., Middleditch, M., Sperry, J., Bashiri, G., & Leung, I. K. H. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00301h · Cited by 71
Applications of covalent chemistry in targeted protein degradation
Lu, D., Yu, X., Lin, H., Cheng, R., Monroy, E. Y., Qi, X., Wang, M. C., & Wang, J. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00362g · Cited by 72
Corso, A. D., Catalano, M., Schmid, A. S., Scheuermann, J., & Neri, D. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201811650 · Cited by 71
Recent progress in covalent warheads for in vivo targeting of endogenous proteins
Shindo, N., & Ojida, A. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116386 · Cited by 71
Catalytic Metallodrugs: Substrate‐Selective Metal Catalysts as Therapeutics
Yu, Z., & Cowan, J. A. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201701714 · Cited by 68
Baggio, C., Udompholkul, P., Gambini, L., Salem, A. F., Jossart, J. N., Perry, J. J. P., & Pellecchia, M. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01108 · Cited by 68
Ligand Conformational Bias Drives Enantioselective Modification of a Surface-Exposed Lysine on Hsp90
Cuesta, A., Wan, X., Burlingame, A. L., & Taunton, J. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.9b09684 · Cited by 68
Akbar, A., McNeil, N. M. R., Albert, M. R., Ta, V., Adhikary, G., Bourgeois, K., Eckert, R. L., & Keillor, J. W. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01070 · Cited by 67
Targeting Epigenetic Regulators with Covalent Small-Molecule Inhibitors
Zhang, Y., Rong, D., Li, B., & Wang, Y. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02055 · Cited by 63
Docking of Covalent Ligands: Challenges and Approaches
Sotriffer, C. (2018) · Molecular Informatics · doi:10.1002/minf.201800062 · Cited by 63
Structural basis of intron selection by U2 snRNP in the presence of covalent inhibitors
Cretu, C., Gee, P., Liu, X., Agrawal, A. A., Nguyen, T.-V., Ghosh, A. K., Cook, A. S., Jurica, M. S., Larsen, N., & Peña, V. (2021) · Nature Communications · doi:10.1038/s41467-021-24741-1 · Cited by 65
Protein Labeling and Crosslinking by Covalent Aptamers
Tivon, Y., Falcone, G. N., & Deiters, A. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202101174 · Cited by 65
Kinetic Optimization of Lysine-Targeting Covalent Inhibitors of HSP72
Pettinger, J., Carter, M., Jones, K., & Cheeseman, M. D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01709 · Cited by 77
Covalent peptides and proteins for therapeutics
Berdan, V. Y., Klauser, P. C., & Wang, L. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115896 · Cited by 61
How Reactive are Druggable Cysteines in Protein Kinases?
Awoonor‐Williams, E., & Rowley, C. N. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00454 · Cited by 58
Drug design targeting active posttranslational modification protein isoforms
Meng, F., Liang, Z. T., Zhao, K., & Luo, C. (2020) · Medicinal Research Reviews · doi:10.1002/med.21774 · Cited by 61
Chan, A. H., Lee, W., Spasov, K. A., Cisneros, J. A., Kudalkar, S. N., Petrova, Z. O., Buckingham, A. B., Anderson, K. S., & Jorgensen, W. L. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711463114 · Cited by 56
The Proteome‐Wide Potential for Reversible Covalency at Cysteine
Senkane, K., Vinogradova, E. V., Suciu, R. M., Crowley, V. M., Zaro, B. W., Bradshaw, J. M., Brameld, K. A., & Cravatt, B. F. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201905829 · Cited by 58
Approaches to mitigate the risk of serious adverse reactions in covalent drug design
Baillie, T. A. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1832079 · Cited by 57
Self-citation
Metadata
- Authors
- Baillie, T. A.
- Affiliations
- University of Washington (US)
- Corresponding author
- Baillie, Thomas A.
- ORCID
- Baillie, Thomas A.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2016-08-19
- Volume
- 55
- Issue
- 43
- Pages
- 13408-13421
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2517550655
- Cited by
- 578
- References
- 118
- Citations by year
- 2026: 55 · 2025: 77 · 2024: 66 · 2023: 46 · 2022: 49 · 2021: 76 · 2020: 72 · 2019: 52 · 2018: 46 · 2017: 31 · 2016: 5
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Angewandte Chemie International Edition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- targeted covalent inhibitors, covalent drug design, drug toxicity, enzyme inhibitors, receptor modulators, drug discovery, non-covalent binding
- MeSH terms
- Animals, Enzyme Inhibitors, Humans, Ligands, Protein Kinases, Drug Design, Molecular Structure, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.